Logotype for Dogwood Therapeutics Inc

Dogwood Therapeutics (DWTX) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dogwood Therapeutics Inc

Q3 2026 earnings summary

6 Nov, 2026

Executive summary

  • Completed the 239-patient Halneuron® Phase 2b trial for chemotherapy-induced neuropathic pain (CINP); top-line results expected in November 2026.

  • Fully enrolled 95 patients in the 12-week open-label extension; completion expected in early 2027.

  • Cash of $4.9M at September 30 plus the $5.0M October placement is expected to fund operations through Q1 2027.

Financial highlights

  • Q3 licensing revenue was $100K, the first payment under the PRIDCor License Agreement; cost of goods sold was $88.1K and gross profit was $11.9K.

  • Q3 R&D expense was $3.3M vs. $14.5M YoY, primarily reflecting the prior-year $12.0M acquired IPR&D charge, partly offset by higher Halneuron® costs.

  • Q3 G&A expense was $1.6M vs. $1.3M YoY, primarily due to higher salaries and personnel costs.

  • Q3 operating expenses were $4.93M vs. $15.81M YoY; 9M expenses were $24.07M vs. $24.16M.

  • 9M R&D expense fell to $9.27M from $19.53M, primarily reflecting the prior-year acquired IPR&D charge, partly offset by higher Halneuron® trial costs.

Outlook and guidance

  • Halneuron® Phase 2b CINP top-line results are expected in November 2026; final data from the 12-week open-label extension are expected in early 2027.

  • SP16 IV Phase 1b patient dosing is projected to begin in the coming months; the initial safety trial is funded by an NCI grant.

  • Cash and October placement proceeds are expected to fund operations through Q1 2027; additional financing is needed beyond that period.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Dogwood Therapeutics